Weber J - Search Results

1

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.

Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: weber j. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.

2

A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.

Lewis KD, Gibbs P, O'Day S, Richards J, Weber J, Anderson C, Zeng C, Baron A, Russ P, Gonzalez R. Lewis KD, et al. Among authors: weber j. Cancer Invest. 2005;23(4):303-8. doi: 10.1081/cnv-58832. Cancer Invest. 2005. PMID: 16100942 Clinical Trial.

3

Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.

Weber J, Boswell W, Smith J, Hersh E, Snively J, Diaz M, Miles S, Liu X, Obrocea M, Qiu Z, Bot A. Weber J, et al. J Immunother. 2008 Feb-Mar;31(2):215-23. doi: 10.1097/CJI.0b013e3181611420. J Immunother. 2008. PMID: 18481391 Clinical Trial.

4

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Weber J. Weber J. Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Oncologist. 2008. PMID: 19001147 Free article. Review.

5

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Weber JS, et al. J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018089 Clinical Trial.

6

Ipilimumab: controversies in its development, utility and autoimmune adverse events.

Weber J. Weber J. Cancer Immunol Immunother. 2009 May;58(5):823-30. doi: 10.1007/s00262-008-0653-8. Epub 2009 Feb 6. Cancer Immunol Immunother. 2009. PMID: 19198837 Free PMC article. Review.

7

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E, Wagner S. Weber JS, et al. Cancer. 2009 Sep 1;115(17):3944-54. doi: 10.1002/cncr.24473. Cancer. 2009. PMID: 19536884 Free article. Clinical Trial.

8

Recent advances using anti-CTLA-4 for the treatment of melanoma.

Sarnaik AA, Weber JS. Sarnaik AA, et al. Cancer J. 2009 May-Jun;15(3):169-73. doi: 10.1097/PPO.0b013e3181a7450f. Cancer J. 2009. PMID: 19556898 Review.

9

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. Weber J, et al. Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671877 Clinical Trial.

10

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. Hersh EM, et al. Among authors: weber js. Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16. Invest New Drugs. 2011. PMID: 20082117 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,212 results

Search Page

Filters